Memo Therapeutics completes enrolment in trial of potravitug for BK viremia

Memo Therapeutics (MTx) has completed patient enrolment for its US-based Phase II clinical trial of potravitug, a monoclonal antibody aimed at combating BK viremia (BKV) in kidney transplant recipients.